Genmab A/S (GNMSF) Receivables - Other (2023 - 2026)
Genmab A's (GNMSF) quarterly Receivables - Other came in at $62.0 million in Q4 2025, up 26.53% YoY from $49.0 million in Q4 2024, and up 26.53% on a QoQ basis from $49.0 million in Q4 2024.
Genmab A/S (GNMSF) Receivables - Other (2023 - 2026) Analysis & Trends
Genmab A (GNMSF) has 3 years of Receivables - Other data on file, last reported at $62.0 million in Q4 2025.
- Quarterly Receivables - Other rose 26.53% year-over-year to $62.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $62.0 million (up 26.53% YoY) and the FY2025 annual result came in at $62.0 million, up 26.53% from the prior year.
- Receivables - Other rose to $62.0 million in Q4 2025, from $49.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $62.0 million in Q4 2025 to a low of $43.0 million in Q4 2023.
- A 3-year average of $51.3 million and a median of $49.0 million in 2024 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2024 — Receivables - Other gained 13.95% — and 2025, when it grew 26.53%.
- Tracing GNMSF's Receivables - Other over 3 years: stood at $43.0 million in 2023, then grew by 13.95% to $49.0 million in 2024, then increased by 26.53% to $62.0 million in 2025.
- The last three Receivables - Other figures came in at $62.0 million (Q4 2025), $49.0 million (Q4 2024), and $43.0 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.00 Mn |
| Jun 30, 2026 | 48.00 Mn |
| Dec 31, 2025 | 62.00 Mn |
| Dec 31, 2025 | 62.00 Mn |
| Dec 31, 2024 | 49.00 Mn |
| Dec 31, 2024 | 49.00 Mn |
| Dec 31, 2023 | 43.00 Mn |
| Dec 31, 2023 | 43.00 Mn |